Gamble Jones Investment Counsel decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 16.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,269 shares of the biopharmaceutical company’s stock after selling 4,294 shares during the period. Gamble Jones Investment Counsel’s holdings in Gilead Sciences were worth $1,576,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Keel Point LLC boosted its holdings in shares of Gilead Sciences by 0.4% in the 1st quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 11 shares during the last quarter. West Oak Capital LLC increased its stake in shares of Gilead Sciences by 0.7% in the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after acquiring an additional 32 shares during the period. First Heartland Consultants Inc. increased its stake in shares of Gilead Sciences by 0.4% in the second quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock worth $632,000 after acquiring an additional 39 shares during the period. Westover Capital Advisors LLC increased its stake in shares of Gilead Sciences by 0.8% in the first quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock worth $378,000 after acquiring an additional 46 shares during the period. Finally, ARS Investment Partners LLC increased its stake in shares of Gilead Sciences by 0.9% in the first quarter. ARS Investment Partners LLC now owns 5,610 shares of the biopharmaceutical company’s stock worth $381,000 after acquiring an additional 50 shares during the period. Institutional investors own 73.99% of the company’s stock.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 83.52 on Tuesday. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The firm has a 50-day moving average price of $79.84 and a 200-day moving average price of $71.30. The stock has a market cap of $109.07 billion, a P/E ratio of 9.07 and a beta of 1.14.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company’s revenue was down 8.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.08 earnings per share. On average, analysts anticipate that Gilead Sciences, Inc. will post $8.78 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were given a dividend of $0.52 per share. The ex-dividend date was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.49%. Gilead Sciences’s dividend payout ratio (DPR) is currently 22.58%.

In other news, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the sale, the chief financial officer now owns 43,352 shares in the company, valued at $3,684,920. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gregg H. Alton sold 40,000 shares of the firm’s stock in a transaction on Friday, July 21st. The stock was sold at an average price of $74.00, for a total value of $2,960,000.00. Following the sale, the executive vice president now owns 137,488 shares in the company, valued at approximately $10,174,112. The disclosure for this sale can be found here. Insiders sold a total of 388,486 shares of company stock valued at $31,178,297 over the last ninety days. 1.30% of the stock is owned by corporate insiders.

Several brokerages recently issued reports on GILD. Argus raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price for the company in a report on Thursday, August 31st. Deutsche Bank AG reaffirmed a “buy” rating and issued a $81.00 price target on shares of Gilead Sciences in a report on Thursday, August 31st. Credit Suisse Group reaffirmed an “outperform” rating and issued a $85.00 price target (up from $79.00) on shares of Gilead Sciences in a report on Tuesday, August 29th. BidaskClub raised Gilead Sciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Finally, Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $83.66 price target on the stock in a research report on Monday, June 26th. Eleven analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $84.29.

WARNING: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/10/03/gilead-sciences-inc-gild-shares-sold-by-gamble-jones-investment-counsel.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.